[Unrelated donor peripheral blood stem cell transplantation for hematologic malignancies].
This study was aimed to explore feasibility and efficacy of unrelated donor peripheral blood stem cell transplantation (UD-PBSCT) in treatment of hematologic malignancies. Ten patients with hematologic malignancies underwent high resolution DNA based typing HLA-matched or 1 locus mismatched UD-PBSCT. Busulfan, cyclophosphamide, Ara-C, MeCCNU and antithymocyte globulin (ATG) were used for preconditioning regimen in all cases. All patients received mycophenolate mofetile, cyclosporin A and short-term methotrexate with CD25 antibody as the graft-versus-host disease (GVHD) prophylaxis. The results showed that rapid engraftment was observed in all cases who presented full donor chimerism at 28 days post transplantation by STR-PCR. The median time of neutrophil recovery > 0.5 x 10(9)/L, platelet recovery > 20 x 10(9)/L was 13, 17.5 days respectively after transplantation. The incidence of acute GVHD was 3 cases (one case with grade I was recovered from GVHD by himself, one case with grade III was cured, one case with grade VI was died). It is concluded that above-mentioned preconditioning regimen and GVHD prophylaxis are effective approaches for unrelated donor peripheral blood stem cell transplantation in hematopoietic malignancies.
Gao
Chun-Ji
CJ
Department of Hematology, General Hospital of China PLA, Beijing 100853, China. gaochunji@hotmail.com
DA
Wan-Ming
WM
Zhang
Bo-Long
BL
Han
Xiao-Ping
XP
Jing
Yu
Y
Li
Hong-Hua
HH
Bo
Jian
J
Zhu
Hai-Yan
HY
Jin
Hai-Jie
HJ
Wu
Xiao-Xiong
XX
Wang
Quan-Xun
QX
Li
Su-Sia
SS
Huang
Wen-Rong
WR
Yu
Li
L
D000293:Adolescent; D000328:Adult; D001782:Blood Donors; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control*; D006801:Humans; D008297:Male; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy*